Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America - SAN DIEGO, March 4, 2025 /PRNewswire/ --...